Pharmacological treatment options of hand osteoarthritis (hand OA) are limited. Hydroxychloroquine (HCQ) has been used successfully in the treatment of mild rheumatoid arthritis for many years and is believed to be beneficial in hand OA as well. In this trial we studied the symptom modifying effect of HCQ in primary hand OA.
Objectives
Pharmacological treatment options of hand osteoarthritis (hand OA) are limited. Hydroxychloroquine (HCQ) has been used successfully in the treatment of mild rheumatoid arthritis for many years and is believed to be beneficial in hand OA as well. In this trial we studied the symptom modifying effect of HCQ in primary hand OA.
Trial design 
Conclusions
This study shows that 24 weeks of treatment with HCQ in symptomatic hand OA did not reduce pain when compared to placebo. Also, no difference was observed in change of AUSCAN scores or AIMS2-SF scores between both treatment groups.
These results suggest that HCQ should not be prescribed in patients with primary hand OA with mild to moderate pain symptoms.
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